

April 22, 2011



Molecular Templates to Present Preclinical Data on Engineered Toxin Bodies (ETB) at the 5th Annual RNAi and miRNA World Congress

Presentation will include a report on the ETB mediated targeted delivery of RNAi payloads

GEORGETOWN, Texas--(BUSINESS WIRE)-- Molecular Templates, Inc., a biopharmaceutical company focused on the discovery and development of a new class of small biologic therapies called Engineered Toxin Bodies (ETB), announced today that it will present preclinical data in a poster presentation at the 5th Annual RNAi and miRNA World Congress in Boston, MA during April 26-27, 2011. In a presentation, entitled "Engineered Toxin Bodies (ETB) Deliver siRNA Payloads to the Cytosol of Targeted Cells," the company will report the development of ETBs that are capable of delivering siRNA molecules in a target and cell specific manner. ETBs possess biological active properties that allow them to target and internalize against specific extracellular receptors and then mediate their own intracellular translocation to the cytosol to deliver various therapeutic payloads.

"We look forward to presenting these early preclinical data that demonstrates the unique and broad applications of our ETB platform technology," said Eric Poma, president and chief executive officer of Molecular Templates. "ETBs represent a new class of targeted biologics with predictable pharmacokinetics that have active intracellular properties that uniquely positions us to address delivery of RNAi molecules in a target directed manner."

The schedule for the poster presentation is as follows:

Date & Time:	Tuesday, Apr 26, 2011 starting at 1:30 PM (EDT)
	Wednesday, Apr 27, 2011 starting at 1:15 PM (EDT)
Poster Title:	Engineered Toxin Bodies (ETB) Deliver siRNA Payloads to the Cytosol of Targeted Cells
Poster Number:	123
Location:	Boston Park Plaza Hotel & Towers 50 Park Plaza at Arlington Street

About Molecular Templates

Molecular Templates is a venture-backed biopharmaceutical company focused on the discovery and development of a new class of targeted biologic therapeutics called Engineered Toxin Bodies (ETB) platform technology. The company is pursuing development of various ETBs across a wide range of disease areas including cancer, autoimmune, and infectious disease. For more information, visit www.moleculartemplates.com.

Source: Molecular Templates, Inc.